Home
Who We Are
Who We Are
Testimonials
Collaborations
Consulting
Inspection Readiness
GxP Auditing
Quality Systems
Quality Risk Management
Monitoring Services
Training
GCP Training Services
Training Courses
DIGR-ACT
DIGR-ACT - Home
DIGR-ACT - About
DIGR-ACT - Contact Us
Online Store
Catalog
Blog
Contact

Clinical Pathways

Home
Who We Are
Who We Are
Testimonials
Collaborations
Consulting
Inspection Readiness
GxP Auditing
Quality Systems
Quality Risk Management
Monitoring Services
Training
GCP Training Services
Training Courses
DIGR-ACT
DIGR-ACT - Home
DIGR-ACT - About
DIGR-ACT - Contact Us
Online Store
Catalog
Blog
Contact
July 15, 2025
Guest User
Progress Update on the BsUFA III Regulatory ...

07/14/2025

-

In January 2025, the US Food and Drug Administration (FDA) posted a progress update video about the third iteration of the Biosimilar User Fee Act (BsUFA III) regulatory science pilot program by sharing results from recent studies, outcomes of round table discussions, and upcoming milestones.

Progress Update on the BsUFA III Regulatory Science Pilot Program
July 8, 2025
Guest User
New Final Guidance Q&A on RRAs

07/08/2025

-

In June 2025, The US Food and Drug Administration (FDA) released the final guidance titled; “Conducting Remote Regulatory Assessments Questions and Answers” to facilitate understanding about what a remote regulatory assessment (RRA) is expected from establishments when the FDA initiates or requests an RRA.

New Final Guidance Q&A on RRAs
June 23, 2025
Guest User
BIMO Finds Objectionable Conditions During ...

06/23/2025

-

On June 5, 2025, the US Food and Drug Administration (FDA) issued a warning letter and FDA Form 483 to an investigator as a result of objectional conditions observed during a Bioresearch Monitoring Program (BIMO) inspection. According to the letter, the investigator did not adhere to the applicable statutory requirements of Title 21 CFR part 312.60 which states: “An investigator is responsible for ensuring that an investigation is conducted according to the signed investigator statement, the investigational plan, and applicable regulations”.

BIMO Finds Objectionable Conditions During Inspection
June 17, 2025
Guest User
FDA shares FAQs on IRBs

06/17/2025

-

In February 2025 the US Food and Drug Administration (FDA) posted a series of frequently asked questions (FAQ) on their website from the public regarding Institutional Review Boards (IRB) and the protection of human subjects in research.

FDA shares FAQs on IRBs
June 3, 2025
Guest User
Final Guidance Released on IRB Written ...

06/03/2025

-

In February 2025, the US Food and Drug Administration (FDA) and the Department of Health and Human Services (HHS) Office for Human Research Protection (OHRP) released the final guidance “Institutional Review Board (IRB) Written Procedures.”

Final Guidance Released on IRB Written Procedures
Sandra Sather
September 17, 2014

SEPTEMBER 26th 6th Annual CR Symposium: Study Optimization NYM ACRP Chapter Event

Sandra Sather
September 17, 2014

09/17/2014

The 6th Annual Clinical Research Symposium, Study Optimization: Strategies to Enhance Recruitment, Monitoring, and Trial Performance is almost upon us! 

Sandra Sather
September 3, 2014

Another FDA Investigator Warning Letter posted lessons learned: Records Discarded Before NDA Approval

Sandra Sather
September 3, 2014

09/03/2014

A new FDA investigator warning letter was distributed, and here's what you need to know about it!

Sandra Sather
August 20, 2014

New FDA Investigator Warning Letter posted lessons learned

Sandra Sather
August 20, 2014

08/20/2014

The FDA recently posted another Warning Letter for a clinical investigator!

Sandra Sather
August 5, 2014

Does PHI reviewed remotely have to be redacted?

Sandra Sather
August 5, 2014

08/05/2014

Q: Is it necessary to redact subject identifier information if collected by a sponsor for monitoring/verification purposes as long as the site has obtained a valid ICF/HIPAA authorization?

Sandra Sather
July 26, 2014

Data Use Agreements and Remote Monitoring --- What do you think?

Sandra Sather
July 26, 2014

07/26/2014

Under the HIPAA Privacy Rule, a covered entity (CE) may use a Data Use Agreement to allow for a Limited Data Set of PHI to be used and disclosed for a particular purpose without an individual authorization. This type of process should be supported by SOPs within the CE related to compliance with the applicable regulations (45 CFR 164.514 (b)).

Newer Posts
Older Posts
 
Archive List
  • 2013 6
  • 2014 31
  • 2015 25
  • 2016 21
  • 2017 31
  • 2018 55
  • 2019 56
  • 2020 63
  • 2021 50
  • 2022 39
  • 2023 27
  • 2024 25
  • 2025 21

Subscribe to Blogs and Newsletters.

By signing up, you agree to our our Privacy Policy. You may unsubscribe from emails at any time.

Thank you! You will receive a confirmation email shortly.

Back to Top
Clinical Pathwaysinfo@clinicalpathwaysresearch.com

Cookie Notice | License Agreement | Privacy Policy | Return Policy | Terms and Conditions | Data Security Policy | Confidentiality Policy

© 2025 Clinical Pathways. All rights reserved.